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Abstract
Background: Plasmodium falciparum chloroquine resistance (CQR) transporter protein (PfCRT) is known to be the
important key of CQR. Recent studies have definitively demonstrated a link between mutations in the gene pfcrt
and resistance to chloroquine in P. falciparum. Although these mutations are predictive of chloroquine resistance,
they are not quantitatively predictive of the degree of resistance.
Methods: In this study, a total of 95 recently adapted P. falciparum isolates from Thailand were included in the
analysis. Parasites were characterized for their drug susceptibility phenotypes and genotypes with respect to pfcrt.
From the original 95 isolates, 20 were selected for complete pfcrt sequence analysis.
Results: Almost all of the parasites characterized carried the previously reported mutations K76T, A220S, Q271E,
N326S, I356T and R371I. On complete sequencing, isolates were identified with novel mutations at K76A and
E198K. There was a suggestion that parasites carrying E198K were less resistant than those that did not. In addition,
pfcrt and pfmdr1 gene expression were investigated by real-time PCR. No relationship between the expression level
of either of these genes and response to drug was observed.
Conclusion: Data from the present study suggest that other genes must contribute to the degree of resistance
once the resistance phenotype is established through mutations in pfcrt.
Background
Malaria, especially that caused by Plasmodium falci-
parum, is a serious health problem in many tropical
countries and this situation is made worse as a conse-
quence of drug resistance. The 4-aminoquinoline chlor-
oquine (CQ) was introduced in the 1940’s as a cheap
and effective treatment for malaria. Chloroquine-resis-
tant (CQR) parasites were first reported in the late
1950s from South-East Asia and South-America. Since
those early reports, CQR P. falciparum has spread
throughout the malaria endemic world. In addition, in
some areas such as the Thai-Myanmar and the Thai-
Cambodian borders, parasite populations resistant
to most available drugs have evolved. These parasites
have been referred to as multidrug-resistant (MDR)
P. falciparum [1].
Reduced dug accumulation is a phenotypic feature of
CQR which can be partially reversed by the calcium
channel blocker verapamil, an agent that also reverses
chloroquine resistance [2-5]. Two genes have been linked
with this phenotype namely pfmdr1 and pfcrt. The
pfmdr1 gene is located on chromosome 5 and pfcrt gene
is located on chromosome 7. The weight of molecular
evidence suggests that while pfmdr1 may have a modula-
tory effect in parasite susceptibility to CQ [6], mutation
in pfcrt is the principal determinant of CQR [7].
Several mutations have been identified in the pfcrt gene.
CQR P. falciparum strains from South East Asia and
Africa carry point mutations at codons 74, 75, 76, 220,
271, 326 and 371, whereas, CQR South American parasites
carry point mutations at codons 76, 220 and either 72, 326
and 356 or 75, 97 and 371 [8]. The (K76T) mutation is
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strongly associated with CQ susceptibility and clinical out-
comes. Transfection studies have confirmed the impor-
tance of this amino acid change [9]. The PfCRT protein is
localized to the digestive vacuole membrane and appears
to be an integral membrane protein with an as yet uniden-
tified transport function. Hypotheses have been proposed
to explain CQR that implicate PfCRT function as either an
ion channel or as a direct drug transporter. In addition to
mutation in pfcrt being involved in CQR, it has also been
suggested that the level of pfcrt expression has an impact
on parasite susceptibility [10]. Waller et al demonstrated
that lines transfected with pfcrt alleles associated with
CQR displayed a 30-40% reduction in protein expression
together with an increase in CQ sensitivity [10]. In con-
trast, Durrand et al failed to identify any correlation
between the CQ response of field isolates and pfcrt gene
expression [11].
It is generally accepted that PfCRT is the principal
determinant of CQR. However, it is not possible to pre-
dict the degree of CQR based on the pfcrt genotype
alone or even in combination with pfmdr1 genotype. It
is clear form our own surveillance studies and those of
others that parasites considered to be CQR in actual
fact display a broad range of sensitivity to the drug. In
this study, the phenotype-genotype relationship between
95 recently adapted isolates of P. falciparum from Thai-
land were characterized. Furthermore, 20 selected iso-
lates were fully sequenced for pfcrt gene in order to
look for novel mutations that might be implicated in the
degree of CQR.
Methods
Parasite isolates
Clinical P. falciparum isolates were collected from
malaria endemic areas of Thailand including the Thai-
Myanmar (Kanchanaburi, Tak, Ratchaburi and Ranong
Provinces) and Thai-Combodian borders (Chantaburi
Province) between 1998 and 2003 prior to the initiation
of antimalarial treatment. Blood samples from individual
patients were collected under a clinical protocol
approved by the Ethics Committee of the Ministry of
Public Health of Thailand. Briefly, three to five millili-
tres of blood were collected into EDTA tubes from
patients with a confirmed diagnosis of uncomplicated
P. falciparum malaria. The fresh blood samples were
then centrifuged to remove the buffy coat and cryopre-
served in liquid nitrogen following the method of Rowe
et al [12] before being transported to Pharmacology and
Toxicology Unit, Graduate Programme in Biomedical
Sciences, Thammasat University.
Parasite culture and drug susceptibility assay
Parasites were maintained in in vitro culture using the
method of Trager and Jensen [13]. In vitro susceptibility
to chloroquine and a series of related compounds, in
the presence or absence of verapamil was tested by
monitoring [3H]Hypoxanthine uptake [14]. Briefly, each
drug was prepared as 10 mM in 50% ethanol for stock
solution, and further diluted with RPMI-1640 complete
media in desired concentrations. Each well in 96-well
plate contained 100 ml of drug solution and 10 ml of
1% parasitaemia and 20% haematocrit. The plates were
incubated at 37°C in gas chamber (95% N2, 5%O2, 5%
CO2) for 24 hours, then pulsed with 5 ml of [
3H]
hypoxanthine solution (0.1 mCi/ml), and reincubated for
an additional 24 hours. The plates were harvested and
measured with a 1450 MicroBeta Trilux liquid scintilla-
tion and luminescence counter (Wallac Co. Ltd., Fin-
land). The drug concentration that inhibited 50%
parasite growth (IC50) were determined.
PCR amplification of P. falciparum genes
Genomic DNA was extracted using Chelex-resin
(Biorad, USA) according to the method of Wooden et al
[15]. Genetic variation between parasites was investi-
gated by a multiplex PCR fingerprint technique [15].
Previously published nested and allele-restricted PCR
methods were employed to detect pfmdr1 N86Y [16]
and pfcrt mutations [7] respectively. For all assays, the
laboratory adapted Thai K1 parasite isolate was used as
a positive control for the mutant genotype and the
Gambia isolate, G112 (a gift from the Malaria Research
Unit, Chulalongkorn University, Thailand) as a positive
control for the wild type genotype.
DNA sequencing analysis
The pfcrt gene was amplified from genomic DNA using
a nested PCR strategy. Exons 1-2, 3-8 and 9-13 were
sequenced independently using the primers shown in
Table 1. Each reaction contained 1.5 mM MgCl2,
200 mM dNTPs, 1 mM each primer, 1× PCR buffer and
2 U of Taq polymerase (Promega, USA) in a total
volume of 50 ml. The thermal cycle conditions were 94°
C for 3 min, and 35 cycles of 92°C for 30 sec, 55°C for
30 sec, 62°C for 1 min 30 sec and a final extension at
62°C for 5 min. The second round of amplification for
exon 1-2 was 94°C for 4 min, 35 cycles of 92°C for1
min, 60°C for 1 min, 72°C for 1 min and a final exten-
sion step of 72°C for 5 min. PCR products were purified
using Wizard SV gel and PCR clean up system (Pro-
maga, USA) according to the manufacturers instruc-
tions. Each amplicon was then cloned with the TOPO
TA Cloning kit (Invitrogen Life Technologies) and the
positive clones were picked from white or blue colonies
following overnight incubation in selection media, S-Gal
(Sigma, USA). The plasmid DNA was purified using
a MiniPrep Kit (Promega, USA) and digested with
the restriction enzyme EcoRI to confirm the correct
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insertion. Finally, sequencing was carried out using the
M13 forward and reverse primers and DNAstar (Laser-
gene) was utilized for sequence analysis.
Pfcrt and pfmdr1 real-time reverse transcription PCR
quantification
Pfcrt and pfmdr1 gene expression were determined by
real-time reverse transcription PCR. Since pfcrt and
pfmdr1 have previously been reported to be preferen-
tially expressed during the trophozoite state, analysis
was restricted to isolates at the trophozoite stage. Total
RNA was extracted by standard methodology using Tri-
zol™ (Invitrogen, USA) [17]. For pfcrt, EF-1a primers
were designed to cross introns. However, this was not
possible for pfmdr1 since it is a one-exon gene. There-
fore, each sample was treated with DNase prior to
reverse transcription (Invitrogen, USA) in order to
negate the possibility of amplifying genomic DNA. The
sequences of forward and reverse primers as well as the
sequences of the specific reporter probes (FAM-labelled
in all cases) are shown in Table 1. Quantification was
achieved by standard taqMan methodology as previously
reported [18].
Detection of gene copy number of pfmdr1 by SYBR Green I
real-time PCR
Pfmdr1 copy number was determined by SYBR Green I
real-time PCR (iCycler, Bio-Rad, USA) using the default
thermocycler program for all genes: 10 minutes of pre-
incubation at 95°C followed by 40 cycles for 15 seconds
at 95°C and one minute at 60°C. The oligonucleotide
primers were designed by Ferreira [19] with modifica-
tion. Individual real-time PCR reaction was carried out
in 25 μl volume in a 96-well plate containing 1× buffer
(10×), 3.5 mM MgCl2, 200 μM dNTPs, 1 mM each of
sense and antisense primers, 12.5 ml of Platinum™ PCR
SuperMix (Invitrogen, USA). The 2-ΔΔCt method of rela-
tive quantification was adapted to estimate copy num-
bers in P. falciparum genes. In this work, genomic DNA
extracted from P. falciparum 3D7, known to harbour a
single copy of each gene studied, was used as a calibra-
tor, while Pf-b-actin 1 was served as the house-keeping
gene in all experiments. Dd2 genomic DNA was used as
a second calibrator containing four copies of pfmdr1.
A minimum of two experiments was carried out for
each gene and each sample. In each experiment, each
individual sample was run in duplicate wells and the
Ct of each well was recorded at the end of the reaction.
Statistical analysis
All data are expressed as mean ± standard deviation.
Data were assessed for normality using a Shapiro-Wilk
statistical test. A Kruskal-Wallace statistical test was uti-
lized to assess the relationship between mutations in
pfcrt and pfmdr1 and drug IC50. Correlations were
assessed by Spearman Rank test. Statistical significance
for all tests was set at a a = 0.05.
Results
Genetic polymorphisms of P. falciparum isolates
A total of 95 isolates (excluding the laboratory lines: K1,
G112, M12 and T9/94b3) were successfully cultured and
analysed. Of these, 13 were obtained from the Tak Pro-
vince of Thailand, 37 from Kanchanaburi, 16 from
Ranong, 1 from Ratchaburi, and 14 were from Chanta-
burim Provinces. Fourteen isolates were of unknown
origin. Tak, Kanchanaburi and Ranong are provinces
that lie along the Thai-Myanmar border; the first two
areas have been described as ‘high mefloquine-resistance
Table 1 Primers used for pfcrt sequencing and real-time
PCR quantification
Exon 1-2
Primary
E1/2-F CGACATTCCGATATATTATATTTTTAGAC
E1/2-R TATATGTGTAATGTTTTATATTGG
Nested
E1/2-NF CCGTTAATAATAAATACACGCAG
E1/2-NR AATGTTTTATATTGGTAGGTGG
Exon 3-8
Primary
E3/8-F CCACCTACCAATATAAAACATTAC
E3/8-R GTTAAAATATATATAAATGTCTC
Nested
E3/8-NF TATATATATATGTATGTATGTTG
E3/8-NR AATGTCTCTTATAATTTTGAAATT
Exon 9-13
Primary
E9/13-F CTTATAATAAAATTTCAAAATTATAAGAGAC
E9/13-R GAGATCTCTATACCTTCAACATTATTCC
Nested
E9/13-
NF
GAGACATTTATATATATTTTAAC
E9/13-
NR
CCTTATAAAGTGTAATGCG
pfcrt RT-PCR
pfcrt-F CTTTATTTGTATGATTATGTTCTTTATTGTTTATTCCTTATTTGGA
pfcrt-R AACAGGCATCTAACATGGATATAGCAAA
pfcrt-probe TCGGTGTCGTTCTTTTG
pfmdr RT-
PCR
pfmdr-F GCATTCGGTTTTTGGTATGGTACAA
pfmdr-R CCTAATAAAATGGATATAACTGAGGCACCA
pfmdr-probe ACGAATCAATACCCCAATAAT
EF-1a RT-
PCR
EF-1a-F GGCAGAAAGAGAAAGAGGTATTACCA
EF-1a-R CCTGGTGCATCAATGACAGTAAAGA
EF-1a-probe TTATGGAAATTTGAAACCCC
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areas’, whereas the third is described as a ‘low meflo-
quine-resistance area’. Chantaburi Province is located
along the Thai-Cambodian border and is defined as a
‘high mefloquine-resistance area’ (Ministry of Public
Health, Thailand [20].
Based on the results of the PCR fingerprints, all but
two infections were clonal containing only one parasite
population with a single genotype of either msp1, msp2
or csp. Two isolates showed PCR fingerprint suggesting
a mixed-infection. Genotyping for pfcrt revealed a 100%
prevalence of the 76T, 220S, 271E, 326S and 371I muta-
tions (95 of 95 samples) with a 94% prevalence of the
356T Mutation (89 of 95 samples). The K1-type muta-
tion of the pfmdr1 was seen in only 5% (5 of 95) of the
samples with almost all isolates containing the wild type
Asn at position 86.
In vitro drug sensitivity test
A total of 90 isolates were tested for sensitivity to chloro-
quine (CQ), quinine (QN), mefloquine (MQ), and dihy-
droartemisinin (DHA). The sensitivity of the isolates to
CQ and QN was also assessed in the presence or absence
of the resistance reverser verapamil (VP: 5 mM). Sensitiv-
ity of the isolates to CQ, QN and MQ was categorized
based on IC50 values described by Cerutti et al, [21].
CQ sensitivity was categorized into either highly resis-
tant (HR: IC50 >101 nM), moderately resistant (MR:
30.9 <IC50 ≤ 100.9 nM) or sensitive (S: IC50 ≤ 30.9 nM)
(Figure 1A). Based on these criteria, 30 (32%), 61 (64%),
and 4 (4%) isolates were categorized as HR, MR, and S,
respectively. The corresponding values for geometric
mean (95% CI) IC50 were 130.9 (122.1-140.2), 60.8
(56.7-65.3), and 23.0 (20.5-25.5) nM, respectively. All
resistant isolates demonstrated a verapamil reversible
component of resistance.
QN sensitivity was categorized as either resistant (R:
IC50 >500 nM) or sensitive (S: IC50 ≤ 500 nM). Based
on these criteria, 1 (1%), and 92 (99%) isolates were
categorized as R, and S, respectively. The corresponding
values for geometric mean (95% CI) IC50 were 654.4
and 144.4 (129.4-161) nM, respectively. All isolates were
chemosensitized verapamil.
MQ sensitivity was categorized as either resistant (R:
IC50 >24 nM) or sensitive (S: IC50 ≤ 24 nM) (Figure 1B).
Based on these criteria, 44 (32%), and 47 (68%) isolates
were categorized as R, and S, respectively. The corre-
sponding values for geometric mean (95% CI) IC50 were
38.2 (34.4-42.4), and 13.3 (11-16) nM, respectively.
The IC50 of DHA for different isolates ranged from
0.37 to 4.87 nM, with the geometric mean (95% CI) of
1.42 (1.24-1.64) nM.
The relationship between genotype and phenotype
Based on the known mutations in pfcrt and pfmdr1, there
was no statistically significant association between sus-
ceptibility of P. falciparum isolates to CQ, QN and MQ
and pfcrt polymorphisms, as well as between susceptibil-
ity to CQ and QN and pfmdr1 polymorphisms. However,
there was a tendency (no statistical significance) of
reduced MQ susceptibility in pfmdr1 mutant isolates.
Novel sequence polymorphisms in pfcrt
A total of 20 isolates selected from either the moder-
ately or highly CQ resistant subgroups were fully

 
 
 
 
 
 
A B 
Figure 1 Box plot between logIC50 and the order of drug susceptibility. A: CQ was categorised into high resistance (HR: IC50 >101 nM),
moderate resistance (MR: 30.9 <IC50 ≤ 100.9 nM) and sensitive (S; IC50 ≤ 30.9 nM). B: MQ was divided into 2 groups; resistant (R; IC50 >24 nM
and sensitive (S; IC50 ≤ 24 nM).
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sequenced for the pfcrt gene in order to establish if
other, as yet unknown mutations could discriminate
between these two levels of in vitro susceptibility. The
derived sequences were compared with the sequences of
the 3D7 and Dd2 parasites from the PlasmoDB data-
base. The sequencing results are summarized in Table 2.
There were several new mutations identified at a num-
ber of novel positions, which conferred an amino acid
alteration compared to 3D7. However, it was not possi-
ble in this study to directly link these sequence differ-
ences with CQ susceptibility. Although most of the
parasites had the familiar “CVIET” sequence at positions
72-76, the J9 isolate from Chantaburi contained the
novel mutation at codon 76 with a different amino acid
substitution K76A. This is a unique position 76 muta-
tion, which has never been reported before in field iso-
lates. In addition, this field isolate carried other
mutations at positions S39P and N277D.
Four of the field isolates categorized as displaying
moderate CQ resistance carried a E198K mutation
which may be functionally relevant. Furthermore, dele-
tions in the pfcrt sequence were observed at position
327 in isolate BC7 and 251 in isolate KS28. These two
deletions occurred at exon 2. Interestingly, the A144T
or A144F mutation newly described in isolates from the
Philippines and Cambodia was not detected in these
Thai isolates [8,22].
Pfcrt and pfmdr1 gene expression
The correlation between pfcrt and pfmdr1 gene expres-
sion (determined by RT-PCR) and in vitro response is
shown in Figures 2 and 3. In this study, there was no
statistically significant correlation between expression
levels of either gene and sensitivity to CQ, QN or MQ.
Although statistical significance was not achieved, a
trend toward higher pfmdr1 expression levels in MQ
sensitive isolates was observed (p = 0.094).
Interestingly, expression of pfcrt mRNA could not be
detected in two isolates (BC1 and J1) despite confirma-
tion of EF-1a gene expression performed on several
occasions. This was not due to any primer mismatch
and did not appear to relate to experimental difficulties,
although all possibilities cannot be ruled out. This
observation needs to be carefully followed up as it has
been shown that a pfcrt knockout is fatal for the parasite
[10].
Table 2 Sequence polymorphism in pfcrt
Isolate/clone CQ IC50 (nM) Amino acid in pfcrt gene
72 73 74 75 76 198 220 271 326 356 371
3D7 8 C V M N K E A Q N I R
Dd2 48 C V I E T E S E S T I
BC1 76 C V I E T E S E S T I
BC7 54 C V I E T E S E S T I
BC12 49 C V I E T E S E S T I
BC22 42 C V I E T K* S E S T I
BC31 31 C V I E T K* S E S T I
BC35 57 C V I E T K* S E S T I
J1 107 C V I E T E S E S T I
J3 119 C V I E T E S E S T I
J4 114 C V I E T E S E S T I
J5 121 C V I E T E S E S T I
J6 167 C V I E T E S E S T I
J9 123 C V I E A** E S E S T I
KS14 67 C V I E T E S E S T I
KS21 68 C V I E T E S E S T I
KS28 74 C V I E T E S E S T I
KS33 55 C V I E T E S E S T I
KS50 78 C V I E T K* S E S T I
PCM2 75 C V I E T E S E S T I
PCM7 51 C V I E T E S E S T I
RN54 47 C V I E T E S E S T I
* Glutamic acid = > Lysine.
** Lysine == > Alanine.
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Figure 2 Correlation analysis between in vitro responses (logIC50) and relative pfcrt expression in falciparum samples. The analysis was
deduced using the comparative ΔΔCt method (log 2-ΔΔCt) using either EF1-alpha as endogenous control gene.
Figure 3 Correlation analysis between in vitro responses (logIC50) and relative Pfmdr1 expression in falciparum samples. The analysis
was deduced using the comparative ΔΔCt method (log 2-ΔΔCt) using either EF1-alpha as endogenous control gene.
Chaijaroenkul et al. Malaria Journal 2011, 10:42
http://www.malariajournal.com/content/10/1/42
Page 6 of 9
Pfmdr1 copy number
The pfmdr1 copy number was determined by SYBR
Green I real-time PCR. The average copy number of
Dd2 was 4.4, which was similar to that previously
reported [19]. The pfmdr1 gene copy number was
neither correlated to mRNA expression nor in vitro
drug susceptibility.
Discussion
Thailand and its borders have historically been linked
with the early emergence of drug resistant parasites.
The first report of CQ resistance came from this region
in the late 1950’s. MQ resistance was reported shortly
after its deployment, a situation which was worsened
despite doubling the drug dosage for treatment. More
recently, the Malaria Control Programme of Thailand
has introduced artesunate, an artemisinin derivative,
deployed in combination with mefloquine to control
these multidrug resistant parasites. With respect to CQ
susceptibility, molecular studies have confirmed the role
for mutation in the pfcrt gene and CQR with a possible
modulatory influence coming from the pfmdr1 gene. In
contrast, MQ susceptibility has been linked to mutation
[6,23,24] and gene copy number of pfmdr1 [25]. Despite
these linkage data, a wide range of observations cannot
be fully explained by the currently available genetic evi-
dence. In this study, this issue was investigated in more
detail using isolates recently collected from distinct
regions of Thailand.
It is unquestionable that genetic polymorphisms of
parasite transporter genes have affected the susceptibility
to various drugs. In early studies of multidrug resistance
in South East Asia, single nucleotide polymorphisms
(SNPs) in pfmdr1 gene such as N86Y have been identified
[26]. In Africa, where the 4-aminoquinoline is the main
drug for malaria treatment, the frequency of N86Y poly-
morphism is high (>50%) [12,16,27-29]. However the fre-
quency of N86Y mutation observed in the present study
was relatively low, which is in agreement with its fre-
quency in other South East Asian isolates [3,27,30-33].
This might be due to the influence of MQ pressure since
mid 1980s after CQ was dismissed in this region [25,34].
Whilst the association of pfmdr1 polymorphisms and
drug sensitivity is still a matter of debate, the level of
expression of pfmdr1 seems to offer a better explanation
of anti-malarial drug sensitivity profiles, especially for
MQ, QN and artemisinin derivatives. Previous studies
have shown the relationship between the increase of
pfmdr1 gene copy number and multidrug resistance
phenotypes including artesunate [35-39]. In one study,
over-expression of pfmdr1 was found to be correlated
with MQ resistance [40]. On the basis that an increase
of gene copy number or gene over-expression may be
expected to result in a rise in the mRNA, the levels of
pfmdr1 mRNA and copy number were compared. It is
very surprising; the level of mRNA was not correlated
to gene copy number. Results failed to reveal an associa-
tion between pfmdr1 expression or gene copy number
and drug sensitivity. This is analogous to the reported
absence of association between Pgh1 protein expression
and CQ sensitivity [41]. The authors note that two iso-
lates (BC1 and J1), which lack pfcrt expression have dif-
ferent pfmdr1 expression. For the J1 isolate, of which
pfmdr1 expression was approximately 70-fold over BC1,
showed reduced sensitivity to both CQ and MQ.
Although the trend of correlation between pfmdr1
expression and sensitivity to MQ was observed, due to
small number of sample size, a statistically significant
correlation could not be achieved. These data suggest
that increase of copy number and over-expression of
pfmdr1 gene may not necessarily confer drug resistance
on its own. Nevertheless, the expression and poly-
morphism of pfmdr1 may make a major contribution to
drug resistance when present in conjunction with the
mutation of other genes [6].
Several studies have described gene mutations in asso-
ciation with CQ-resistance but the exact mechanism of
resistance remains unclear. The K76T mutation of pfcrt
is reported to be highly associated with CQ-resistance.
The frequency of this mutation is almost 100% in Thai-
land. Consequently there seems to be no link between
the frequency of this gene mutation and CQ sensitivity.
Parasites carrying the K76T mutation with comparable
patterns of other pfcrt gene mutations still showed a
variable degree of CQ-resistance. In fact, the pfcrt poly-
morphisms were similar in all Thai isolates but drug
sensitivity profiles were completely different. Data
reported from other South East Asian countries, i.e.,
Philippines, showed different mutations carrying K76T
and N326D without 220S residue, together with the
novel mutations A144T and L160Y [42]. Furthermore,
four novel mutations A144F, L148I, I194T and T333S
were observed from Cambodian isolates [11]. These
mutation patterns were not observed in Thailand. This
suggests that CQ-resistance emerged simultaneously but
independently in these neighboring endemic regions.
Pfcrt polymorphism pattern CVIET was found in all
isolates. This pattern is unique to P. falciparum isolates
from South East Asia. The CVIET pattern, which is dif-
ferent from SVMNT pattern of South America, is more
responsive to the calcium channel-blocker verapamil.
The chemosensitization phenomenon of verapamil was
observed for all isolates even the isolates with lower sen-
sitivity to CQ. Therefore, the CVIET polymorphism pat-
tern seems to confer chemosensitization by verapamil
and related compounds.
Full pfcrt sequencing revealed the novel 76 haplotype
K76A in one isolate. Previously, the substitution of
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other amino acids at this codon, i.e., K76I and/or K76N
has been reported only in laboratory strains [7,43]. This
allelic type replaces lysine (positively charged amino
acid) with alanine (non-charged amino acid), similar to
the charge loss found with K76T, K76I and K76N muta-
tions. These data augment the growing body of evidence
that substitution of non-charged amino acid appears to
result in resistance of the parasite to CQ. In addition,
the new mutation at position E198K was detected in 4
out of 20 isolates with high CQ sensitivity (low IC50).
Based on amino acid sequence, it is speculated that
E198K might be located in the fifth of ten PFCRT trans-
membrane regions, with substitution of glutamic acid
(negative charge) to lysine (positive charge). The addi-
tional mutation in this position may be critical to the
loss of resistance of these parasites to CQ. These find-
ings may support the proposed hypothesis that CQR
results from a “charged drug leak”, in which the loss of
positive charge in the channel of PfCRT might allow the
protonated species of CQ to leak out of the digestive
vacuole, thus reducing vacuolar CQ concentration and
ultimately conferring resistance [44].
Results obtained from transfection studies showed sig-
nificant correlation between the extent of protein
expression and drug sensitivity profile (increased resis-
tance with increased expression) [10]. In contrast, recent
observation of pfcrt expression and parasites from field
isolates showed no correlation between level of mRNA
expression and CQ sensitivity [11]. In our study, such
absence of correlation between level of mRNA expres-
sion and CQ sensitivity was also observed. Furthermore,
it was found that no mRNA expression was observed in
two isolates. This finding was in contrast with the pre-
vious report showing that the knockout of pfcrt gene
would lead the parasite to death. The undetectable level
of mRNA expression could be explained by the low or
totally absence of pfcrt expression, or the fact that gene
expression may not entirely represent protein expression
due to post-transcription process.
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